全文获取类型
收费全文 | 7736篇 |
免费 | 605篇 |
国内免费 | 69篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 139篇 |
妇产科学 | 145篇 |
基础医学 | 959篇 |
口腔科学 | 115篇 |
临床医学 | 730篇 |
内科学 | 1694篇 |
皮肤病学 | 97篇 |
神经病学 | 706篇 |
特种医学 | 433篇 |
外科学 | 1212篇 |
综合类 | 126篇 |
一般理论 | 2篇 |
预防医学 | 444篇 |
眼科学 | 105篇 |
药学 | 543篇 |
中国医学 | 71篇 |
肿瘤学 | 856篇 |
出版年
2023年 | 71篇 |
2022年 | 130篇 |
2021年 | 235篇 |
2020年 | 149篇 |
2019年 | 229篇 |
2018年 | 216篇 |
2017年 | 171篇 |
2016年 | 230篇 |
2015年 | 271篇 |
2014年 | 354篇 |
2013年 | 413篇 |
2012年 | 599篇 |
2011年 | 620篇 |
2010年 | 382篇 |
2009年 | 332篇 |
2008年 | 487篇 |
2007年 | 453篇 |
2006年 | 392篇 |
2005年 | 378篇 |
2004年 | 341篇 |
2003年 | 287篇 |
2002年 | 252篇 |
2001年 | 178篇 |
2000年 | 144篇 |
1999年 | 130篇 |
1998年 | 63篇 |
1997年 | 40篇 |
1996年 | 41篇 |
1995年 | 37篇 |
1994年 | 22篇 |
1993年 | 24篇 |
1992年 | 64篇 |
1991年 | 74篇 |
1990年 | 72篇 |
1989年 | 56篇 |
1988年 | 60篇 |
1987年 | 55篇 |
1986年 | 46篇 |
1985年 | 30篇 |
1984年 | 29篇 |
1983年 | 29篇 |
1982年 | 20篇 |
1981年 | 17篇 |
1980年 | 17篇 |
1979年 | 16篇 |
1978年 | 23篇 |
1977年 | 16篇 |
1976年 | 20篇 |
1975年 | 13篇 |
1974年 | 20篇 |
排序方式: 共有8410条查询结果,搜索用时 15 毫秒
51.
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. 总被引:11,自引:0,他引:11
Jennifer J Knox David Hedley Amit Oza Ron Feld Lillian L Siu Eric Chen Mahsan Nematollahi Gregory R Pond Jessica Zhang Malcolm J Moore 《Journal of clinical oncology》2005,23(10):2332-2338
PURPOSE: Biliary cancer has a poor prognosis, and chemotherapy has had little impact. The objectives of this trial were to determine the response rate, time to disease progression, survival, and safety profile of the combination of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer. PATIENTS AND METHODS: Eligible patients had pathologically proven, locally advanced or metastatic adenocarcinoma arising from the intra- and extrahepatic bile ducts or gallbladder with no prior chemotherapy. Patients were treated on a 3-week cycle consisting of capecitabine at 650 mg/m(2) orally twice a day for 14 days and gemcitabine at a fixed dose of 1,000 mg/m(2) intravenously over 30 minutes on days 1 and 8. RESULTS: Forty-five patients were enrolled between July 2001 and January 2004. Fifty-three percent of patients had cholangiocarcinoma, 47% had gallbladder cancer, and 89% had metastatic disease. The overall objective response rate was 31%, with an additional 42% of patients with stable disease, for a disease control rate of 73%. The median overall survival time was 14 months (95% CI, 7.3 months to not available), and the median progression-free survival time was 7 months (95% CI, 4.6 to 11.8 months). This chemotherapy combination was generally well tolerated. Transient neutropenia, thrombocytopenia, fatigue, and hand-foot syndrome were commonly observed but were easily managed without discontinuing further treatment. CONCLUSION: The significant antitumor activity combined with a mild toxicity profile seen in this study argue that GemCap chemotherapy may benefit patients with advanced biliary cancer. This regimen warrants further evaluation in a randomized study with survival and quality of life end points. 相似文献
52.
M Moore H W Hirte L Siu A Oza S J Hotte O Petrenciuc F Cihon C Lathia B Schwartz 《Annals of oncology》2005,16(10):1688-1694
BACKGROUND: BAY 43--9006, an oral multi-kinase inhibitor, targets serine-threonine kinases and receptor tyrosine kinases, and affects the tumor and vasculature in preclinical models. Based on its pharmacologic effect, it may be a useful cancer treatment. This study determined the maximum tolerated dose (MTD) of BAY 43-9006 in 42 patients with advanced, refractory metastatic or recurrent solid tumors. Dose-limiting toxicities (DLTs), safety, pharmacokinetics and tumor response were also evaluated. PATIENTS AND METHODS: In this open-label, phase I, dose-escalation study, BAY 43--9,006 was administered orally in repeated cycles of 35 days (28 days on/7 days off). Eight doses were investigated: from 50 mg every fourth day to 600 mg twice daily. Treatment continued until unacceptable toxicity, tumor progression or death. RESULTS: The MTD was 400 mg twice daily. BAY 43-9006 was well tolerated, with mild to moderate toxicities; only six patients discontinued study therapy due to adverse events. DLTs consisted of hand-foot skin reaction in three of seven patients receiving 600 mg twice daily. Stable disease was achieved in 22% of patients; median duration of stable disease was 7.2 months. Consistent with its observed half-life of approximately 27 h, BAY 43-9, 006 accumulated on multiple dosing. Increases in exposure were less than proportional to the increases in dose. CONCLUSIONS: Results indicate that further clinical investigation of BAY 43--9006 is warranted, and suggest it could be a promising future therapy for patients with cancer. 相似文献
53.
Anne W M Lee W H Lau Stewart Y Tung Daniel T T Chua Rick Chappell L Xu Lillian Siu W M Sze T W Leung Jonathan S T Sham Roger K C Ngan Stephen C K Law T K Yau Joseph S K Au Brian O'Sullivan Ellie S Y Pang S K O Gordon K H Au Joseph T Lau 《Journal of clinical oncology》2005,23(28):6966-6975
PURPOSE: This randomized study compared the results achieved by concurrent chemoradiotherapy (CRT) versus radiotherapy (RT) alone for nasopharyngeal carcinoma (NPC) with advanced nodal disease. PATIENTS AND METHODS: Patients with nonkeratinizing/undifferentiated NPC staged T1-4N2-3M0 were randomized to CRT or RT. Both arms were treated with the same RT technique and dose fractionation. The CRT patients were given cisplatin 100 mg/m2 on days 1, 22, and 43, followed by cisplatin 80 mg/m2 and fluorouracil 1,000 mg/m2/d for 96 hours starting on days 71, 99, and 127. RESULTS: From 1999 to January 2004, 348 eligible patients were randomly assigned; the median follow-up was 2.3 years. The two arms were well-balanced in all prognostic factors and RT parameters. The CRT arm achieved significantly higher failure-free survival (72% v 62% at 3-year, P = .027), mostly as a result of an improvement in locoregional control (92% v 82%, P = .005). However, distant control did not improve significantly (76% v 73%, P = .47), and the overall survival rates were almost identical (78% v 78%, P = .97). In addition, the CRT arm had significantly more acute toxicities (84% v 53%, P < .001) and late toxicities (28% v 13% at 3-year, P = .024). CONCLUSION: Preliminary results confirmed that CRT could significantly improve tumor control, particularly at locoregional sites. However, there was significant increase in the risk of toxicities and no early gain in overall survival. Longer follow-up is needed to confirm the ultimate therapeutic ratio. 相似文献
54.
55.
Anti‐fibrotic and Anti‐tumorigenic Effects of Rhein,a Natural Anthraquinone Derivative,in Mammalian Stellate and Carcinoma Cells 下载免费PDF全文
Anthraquinone compounds have been recognized to possess antiinflammatory, anti‐fibrotic and anti‐tumour properties and thus applied in human and veterinary therapeutics as active substances of medicinal products. Amongst the anthraquinones isolated from Rheum palmatum, also known as da‐huang, rhein was detected as one of the highest metabolite contents in the bloodstream of mammals. The biological activities of rhein therefore deserve detailed investigation. In this study, we aimed to delineate the mechanism of inhibitory actions of rhein on fibrotic and tumorigenic processes by means of various biochemical assays, such as immunofluorescent staining, real‐time polymerase chain reaction (PCR) and western blotting analyses in rat pancreatic stellate cells (LTC‐14), human pancreatic ductal adenocarcinoma cells (PANC‐1) and human colon carcinoma cells (SW480 and SW620). Our results demonstrated that the application of rhein notably suppressed the mRNA and protein levels of various fibrotic and tumorigenic mediators including alpha‐smooth muscle actin, type I collagen, fibronectin, N‐cadherin and matrix metalloproteinases in the testing mammalian cells. The mechanism of the suppressive actions of rhein was associated with the modulation of the sonic hedgehog and serine‐threonine kinase signalling pathways. In conclusion, we suggest that rhein may serve as a therapeutic or an adjuvant agent in anti‐fibrotic and anti‐tumorigenic approaches. Copyright © 2014 John Wiley & Sons, Ltd. 相似文献
56.
Yoon Jin Choi Yong Chan Lee Jung Mogg Kim Jin Il Kim Jeong Seop Moon Yun Jeong Lim Gwang Ho Baik Byoung Kwan Son Hang Lak Lee Kyoung Oh Kim Nayoung Kim Kwang Hyun Ko Hye-Kyung Jung Ki-Nam Shim Hoon Jai Chun Byung-Wook Kim Hyuk Lee Jie-Hyun Kim Hyunsoo Chung Sang Gyun Kim Jae Young Jang 《Gut and liver》2022,16(4):535
Background/AimsWe examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.MethodsA randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.ResultsIn total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.ConclusionsTPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier ). NCT03317223相似文献
57.
Davis AJ Gelmon KA Siu LL Moore MJ Britten CD Mistry N Klamut H D'Aloisio S MacLean M Wainman N Ayers D Firby P Besterman JM Reid GK Eisenhauer EA 《Investigational new drugs》2003,21(1):85-97
Purpose: MG98 is a second generation phosphorothioate antisense oligodeoxynucleotide which is a highly specific inhibitor of translation of the mRNA for human DNA MeTase I (DNMT 1). This phase I study examined the toxicity and pharmacologic profile of MG98 administered as a continuous 21-day intravenous infusion every 4 weeks. Patients and methods: Fourteen patients with solid cancers received a total of 25 cycles of MG98 at doses ranging from 40 to 240 mg/m2/day. Steady-state concentrations of MG98 were measured as were several pharmacodynamic assessments including mRNA of the target gene, DNMT1, in PBMC. In addition, other potential surrogate markers of drug effects were explored, including hemoglobin F, Vimentin and GADD45. Results: Dose limiting effects were drug-related reversible transaminase elevation and fatigue seen at doses of 240, 200 and 160 mg/m2/day. The dose level of 80 mg/m2/day was felt to be safe and tolerable when delivered on this schedule. No evidence of antitumor activity was observed. Although pharmacokinetic analysis revealed that at the higher dose levels, mean Css values of MG98 were approximately 10-fold times the IC50 values associated with target inhibition in vitro, the extent of MG98 penetration into target tumors in this trial was not determined. No consistent, dose-related changes in correlative markers including DNMT1 mRNA, hemoglobin F, Vimentin and GADD45, were observed. Conclusions: This schedule of MG98 given as a 21-day continuous intravenous infusion every 4 weeks was poorly tolerated in the highest doses; therefore, further disease-site specific evaluation of the efficacy of this agent will utilize a more favorable, intermittent dosing schedule. Pharmacodynamic evaluations undertaken in an attempt to explore and validate the biological mechanisms of MG98 did not show dose-related effects. 相似文献
58.
59.
60.
Viral infections in pregnancy 总被引:1,自引:0,他引:1
Viral infections are a common complication of pregnancy and in some cases, can have profound effects for the unborn fetus. The human herpesvirus family is composed of large, enveloped DNA viruses that have close structural similarity. The family includes the herpes simplex viruses types 1 and 2, varicella zoster virus, Epstein Barr virus, cytomegalovirus (CMV), and human herpes viruses types 6, 7 and 8. These viruses all share the ability to establish latency and reactivate at a later time. Structural fetal abnormalities can result from intrauterine infection and transmission of the infection during the pregnancy or at the time of delivery can result in important neonatal disease. Human parvovirus B19 is a DNA virus with strong tropism for erythroid precursors and infection during pregnancy can result in fetal hydrops and stillbirth. The causative agents of hepatitis are hepatotropic viruses termed hepatitis A, B, C, D (deltavirus) and E. All except hepatitis B virus are RNA viruses. Vertical transmission of maternal infection with hepatitis B and C can result in significant long term sequelae. 相似文献